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Table 1 – Gliomas in the 2016 WHO classification of primary tumors of the 
central nervous system 
 
Figure 1 – Overview of molecular subtypes of diffuse gliomas 
 
 
 
 
 
 
  
Opinion statement 
 
 
The revised World Health Organization (WHO) classification of tumors of the central 
nervous system of 2016 combines biology driven molecular marker diagnostics with 
classical histological cancer diagnosis. Reclassification of gliomas by molecular 
similarity beyond histological boundaries improves outcome prediction and will 
increasingly guide treatment decisions. This change in paradigms implies more 
personalized and eventually more efficient therapeutic approaches, but the era of 
molecular targeted therapies for gliomas is yet at its onset. Promising results of 
molecularly targeted therapies in genetically less complex gliomas with circumscribed 
growth such as subependymal giant cell astrocytoma or pilocytic astrocytoma support 
further development of molecularly targeted therapies. In diffuse gliomas, several 
molecular markers that predict benefit from to alkylating agent chemotherapy have 
been identified in recent years. For example, co-deletion of chromosome arms 1p and 
19q predicts benefit from to polychemotherapy with procarbazin, CCNU (lomustine) 
and vincristine (PCV) in patients with anaplastic oligodendroglioma, and the presence 
of 1p/19q co-deletion was integrated as a defining feature of oligodendroglial tumors 
in the revised WHO classification. However, the tremendous increase in knowledge of 
molecular drivers of diffuse gliomas on genomic, epigenetic and gene expression 
levels has not yet translated into effective molecular targeted therapies. Multiple 
reasons account for the failure of early clinical trials of molecularly targeted therapies 
in diffuse gliomas, including the lack of molecular entry controls as well as 
pharmacokinetic and pharmacodynamics issues, but the key challenge of specifically 
targeting the molecular backbone of diffuse gliomas is probably extensive clonal 
heterogeneity. A more profound understanding of clonal selection, alternative 
activation of oncogenic signaling pathways and genomic instability is warranted to 
identify effective combination treatments and ultimately improve survival. 
 
 Introduction 
 
Gliomas are a histologically and molecularly heterogenous group of tumors that are 
thought to derive from neuroglial progenitor cells and that account for approximately 
27% of all primary brain tumors and for 80% of malignant primary brain tumors [1]. 
Histologically, the WHO classification of tumors of the central nervous system 
distinguishes astrocytomas, oligodendrogliomas and ependymomas, and assigns 
WHO grades I-IV with respect to the grade of malignancy [2, 3]. By convention, WHO 
grade I and II gliomas were referred to as low-grade and grades III and IV as high-
grade gliomas. Low-grade gliomas comprised all gliomas with circumscribed growth, 
and these are rare and molecularly less complex than diffuse gliomas. The vast 
majority of gliomas are, however, characterized by diffuse growth and heterogenous 
molecular patterns, and tremendous progress of molecular profiling array technologies 
has yielded genomic, epigenetic and gene expression landscapes that have refined 
the understanding and classification of biologically distinct glioma subtypes beyond 
histology [4-6] (Figure 1). These advances were acknowledged with the 2016 revision 
of the WHO classification of tumors of the central nervous system, which includes 
novel classes of diffuse gliomas based on genomic features (Table 1). Molecular 
diagnostics trump discordant histological results and thereby increase diagnostic 
accuracy and prognostic yield compared to previous histology based classifications 
[3]. Accordingly, the division into low grade and high grade gliomas is outdated and 
should be abandoned. 
In parallel to these advances in classifying gliomas, the identification of key drivers of 
malignancy led to novel therapeutic approaches to target the molecular machinery of 
gliomas. Success of such targeted therapies in the molecularly less complex gliomas 
with circumscribed growth support this principle, but the extensive intratumoral 
heterogeneity of diffuse gliomas poses major challenges: First, large numbers of 
molecular alterations in each tumor complicate the differentiation between passenger 
and driver events. Second, targeting a single driver alteration may be ineffective due 
to compensating pathways that are active in parallel or can be readily activated. Third, 
successful targeting of a tumor cell population may be compensated by clonal 
selection of another population that does not bear the targeted alteration. Therefore, a 
profound understanding of the molecular events that initiate and drive the progression 
of gliomas is crucial for the development of molecularly targeted therapies, because 
ultimately only targeting of key disease drivers that are shared by all cells within the 
tumor, or combination therapies can overcome treatment resistance.  
Innovative trial designs have been suggested, such as umbrella trials that incorporate 
molecular profiling at study entry and the subsequent choice of an individually tailored 
therapy that matches the molecular profile of the tumor [7]. The scope of such trial 
designs is exploratory, thus underscoring the necessity to include repeat biopsies to 
enable the assessment of mechanisms of escape or resistance to molecular targeted 
therapies. However, the choice of tested molecular alterations in such trial designs is 
subject to expert opinions and availability of valid inhibitors that, amongst others, 
match the pharmacokinetic issues posed by the blood brain barrier. Technological 
advances such as deep sequencing and single-cell array approaches in tissues 
derived from sequential biopsies or surgeries will shed further light into the 
mechanisms underlying therapy resistance and malignant progression, albeit the 
prospective applicability of such large-scale arrays for clinical decision making or as 
molecular entry controls for clinical trials is still limited by logistic issues such as the 
requirement of extensive financial, human and technological resources, as well as a 
lack of consensus on data interpretation. 
This review will summarize the current knowledge of the molecular background of 
gliomagenesis, the applicability of molecular marker diagnostics derived from this 
knowledge as well as current and future implications for precision medicine in gliomas. 
 
 Gliomas with circumscribed growth  
 
Improved understanding of the molecular basis of gliomas with circumscribed growth 
yielded promising results of molecularly targeted therapies. For example, 
subependymal giant cell astrocytomas (SEGA) are driven by mutations in either of two 
tumor suppressor genes, tuberous sclerosis complex (TSC)-1 and -2 that encode 
hamartin and tuberin, respectively. Loss of either protein yields disinhibition of cell 
growth signaling through mammalian target of rapamycin (mTOR) [8], and the mTOR 
inhibitor everolimus is effective against SEGA [9, 10].  
Pilocytic astrocytoma is likewise considered a single pathway disease that is driven by 
the mitogen-activated protein kinase (MAPK) pathway due to mutations in the 
fibroblast growth factor receptor 1 (FGFR1) or neurotrophic receptor tyrosine kinase 2 
(NTRK2) genes, or due to tandem duplications in a v-Raf murine sarcoma viral 
oncogene homolog B (BRAF) fusion gene [11, 12] and an early phase study of the 
MAPK inhibitor selumetinib in pilocytic astrocytoma has recently completed accrual 
(NCT01089101).  
Pleomorphic xanthoastrocytomas are rare and less well characterized compared to 
other glioma entities. Particularly the mechanisms underlying the rare instances of 
malignant progression remain unclear. However, activating BRAFV600E mutations are 
present in more than half of pleomorphic xanthoastrocytomas [13] and recent reports 
of response to vemurafenib in heavily pretreated patients with recurrent pleomorphic 
xanthoastrocytomas suggest that the presence of the BRAFV600E mutation lends a 
rationale for salvage treatment with drugs like vemurafenib [14, 15], but no prospective 
trials are ongoing to further explore the role of BRAFV600E as a putative molecular target 
in pleomorphic xanthoastrocytomas.  
 
 
Ependymomas 
 
Low-grade ependymomas are characterized by circumscribed growth patterns, but 
diffuse growth and multifocal progression occur frequently in the course of disease. 
Assessment of the v-rel avian reticuloendotheliosis viral oncogene homolog A (RELA)–
C11orf95 fusion gene has recently entered clinical routine, because RELA fusion-
positive ependymomas have been included in the revised WHO classification as an 
entity with high risk for rapid and diffuse growth at diagnosis or during the disease 
course [3, 16]. A total of 9 molecular ependymoma subtypes have been defined, 
including a second high-risk subtype designated posterior fossa A (PF-A). PF-A 
ependymomas comprise the vast majority of posterior fossa ependymomas, but a 
driver alteration of this probably epigenetically driven disease has not yet been 
identified [17]. The standard of care in ependymomas comprises maximum safe 
resection and post-operative radiotherapy [18, 19]. In consideration that approximately 
half of all patients with ependymomas are children and that maximum resection may 
indeed be curative in a substantial fraction of patients, the timing of radiotherapy is a 
key aspect of the mangement of ependymomas, but probably radiotherapy should not 
be delayed in PF-A and RELA fusion-positive high-risk patients. The role of 
chemotherapy for the treatment of ependymomas has remained elusive and mostly 
confined to the recurrent setting [19]. Ongoing trials assess carboplatin-based 
regimens with and without bevacizumab (NCT01295944, NCT01088035), everolimus 
(NCT02155920) as well as a combination of temozolomide and the dual epithelial 
growth factor receptor (EGFR) inhibitor lapatinib (NCT00826241), which is directed 
against the EGFR isotypes Erb1 and Erb2 (HER2/neu), but molecularly targeted 
therapies taking the recent definitions of ependymoma subtypes into account have not 
yet been launched. Molecularly guided trials are complicated by the overall low 
frequency of ependymomas and further restrictions implicated by the apparent 
molecular diversity. 
  
Diffuse oligodendroglial and astrocytic gliomas 
 
Joint efforts of the scientific community in characterizing the complex biology of diffuse 
gliomas culminated in The Cancer Genome Atlas Research Network (TCGA) and 
recent integration of information on exome sequences, DNA copy numbers, 
epigenetics, as well as messenger RNA, microRNA and protein expression identified 
prognostic subgroups of diffuse gliomas that were defined more accurately than by 
histology [6, 20, 21] (Figure 1). Molecular markers that represent a surrogate excerpt 
of these complex analyses are warranted to enable the translation of knowledge 
derived from these complex large-scale analyses into clinical practice (Table 1). Most 
current studies come up with a simplified approach of characterizing three major 
classes of gliomas, defined by isocitrate dehydrogenase (IDH) mutation plus 1p/19q 
codeletion, IDH mutation without 1p/19q codeletion, or IDH wildtype status [20, 22-25]. 
A classification of 5 prognostic adult glioma subgroups has been proposed based on 
the presence of IDH mutations, 1p/19q co-deletions and telomerase reverse 
transcriptase (TERT) promoter mutations [26], and independently of this classification, 
MGMT promoter methylation has emerged as a predictive marker for benefit from 
temozolomide chemotherapy in elderly patients with glioblastoma [27, 28].  
 
IDH mutations. The integration of IDH mutations into the revised WHO classification 
as a primary categorizing molecular alteration of diffuse gliomas has underpinned a 
change in paradigms from a histology-based towards a biology-based categorization 
of gliomas [3]. The conceptual novelty of the 2016 WHO classification is exemplified 
by the close and causal association of mutant IDH with a distinct epigenetic pattern 
designated glioma-CpG island methylator phenotype (G-CIMP) [29, 30]. Oncogenesis 
studies identified IDH mutations as early and possibly initiating events during 
gliomagenesis and demonstrated that the G-CIMP pattern is preserved throughout 
malignant progression of IDH mutated gliomas from WHO grades II through IV [5, 31]. 
The vast majority of histological WHO grade II/III gliomas harbor IDH mutations, but 
only about 10% of glioblastomas [32, 33]. The histological appearance of IDH mutated 
versus wild-type glioblastomas is largely identical, but IDH mutated glioblastomas are 
associated with younger age at diagnosis and a better prognosis. An antibody to 
specifically detect the most common IDH mutation in gliomas IDH1R132H by 
immunohistochemistry is commercially available [34] and additional sequencing to 
detect other IDH1/2 mutations is recommended in patients with WHO grade II or III 
gliomas or young adults with glioblastoma whose tumors show negative 
immunohistochemistry [35]. To date, the detection of IDH mutations has no direct 
therapeutic implications, but refines the prognostic accuracy of the WHO classification. 
 
Co-deletion of chromosome arms 1p and 19q. According to the 2016 WHO 
classification, co-deletion of chromosome arms 1p and 19q is a defining feature of 
oligodendroglial tumors, whereas 1p/19q non-co-deleted tumors are classified as 
astrocytomas [3]. Notably, this molecular definition of neuroglial lineage association 
has outdated the diagnosis of a mixed oligoastrocytic entity, the histological diagnosis 
of which has been debated because of inter-observer variations and which, according 
to the revised WHO classification, may now only be diagnosed in patients that lack 
assessment of 1p/19q status [3, 36]. 1p/19q co-deleted oligodendrogliomas constitute 
a sub-group of IDH mutated gliomas that commonly harbor additional activating 
mutations in the promoter region of TERT. In contrast, oncogenic mutations in the 
tumor suppressor gene TP53 and in the methylome organizer alpha 
thalassemia/mental retardation syndrome X-linked (ATRX) are primarily found in IDH 
mutated astrocytomas and associated with less favorable prognosis [26, 36, 37]. 
Fluorescent in situ hybridization (FISH) and microsatellite analysis for loss of 
heterozygosity are commonly applied to assess 1p/19q status in clinical routine. The 
prognosis of 1p/19q co-deleted gliomas is favorable and malignant progression to 
glioblastoma is rare. Besides diagnostic and prognostic implications, a predictive role 
of 1p/19q co-deletion for benefit from the addition of polychemotherapy with 
procarbazine, CCNU/lomustine and vincristine (PCV) to radiotherapy was identified in 
long-term analyses of two phase III trials in patients with anaplastic oligodendroglial 
tumors at a median follow-up time of more than ten years [38, 39]. Less toxic regimens 
were commonly utilized in clinical practice by the time these results have re-defined 
PCV as the standard of care for 1p/19q co-deleted tumors and the phase III CODEL 
trial is currently exploring whether PCV may be substituted by temozolomide to reduce 
toxicity, without compromising survival (NCT00887146). 
 
Mutations of the telomerase reverse transcriptase (TERT) promoter. TERT 
promoter mutations are present in most diffuse gliomas and confer poor prognosis in 
patients with IDH wild-type, WHO grade II/III diffuse gliomas [26]. This is of particular 
relevance for the management of patients with WHO grade II diffuse gliomas, because 
watchful waiting strategies are considered feasible in patients with favorable 
prognostic features, including age < 40, tumor diameter < 6 cm, lack of midline crossing 
and lack of neurological deficit other than an brain tumor-associated epilepsy [40-42], 
but such strategies are probably not adequate in the poor prognosis subgroup of TERT 
mutated, IDH wild type diffuse gliomas. 
 
Hypermethylation of the O6-methylguanyl DNA methyltransferase (MGMT) 
promoter. The DNA repair protein MGMT counteracts DNA damage conferred by 
alkylating agent chemotherapy. Transcriptional silencing of the MGMT gene due to 
promoter hypermethylation occurs almost invariably in G-CIMP positive, IDH mutated 
diffuse gliomas, as opposed to approximately 50% of G-CIMP negative, IDH wild-type 
diffuse gliomas [26, 43]. MGMT methylation status has a pivotal role for clinical 
decision-making, e.g., in elderly glioblastoma patients, but MGMT does not segregate 
glioma subtypes with distinct gene ontologies. Consequently, MGMT methylation 
status was not included as a segregating feature in the revised WHO classification. Of 
note, different technical approaches and a lack of consensus on data interpretation 
render MGMT status assessments prone to variability [44]. MGMT promoter 
methylation was strongly associated with benefit from chemotherapy with 
temozolomide in the trial carried out by the European Organisation for Research and 
Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) 
that defined adjuvant temozolomide as the standard of care for newly diagnosed 
glioblastoma [45, 46]. In the elderly setting, the superiority of the combination of 
temozolomide and radiotherapy over radiotherapy alone has been confirmed [47]. 
Elderly patients with diffuse gliomas not considered candidates for combined modality 
treatment are commonly treated with monotherapy regimens [48]. Two phase III trials 
in elderly patients with mostly glioblastomas and a smaller fraction of anaplastic 
astrocytomas defined a predictive role of MGMT methylation for response to 
temozolomide versus radiotherapy to guide decision making at primary diagnosis [27, 
28]. The strong association of MGMT methylation with benefit from temozolomide in 
glioblastoma is retained at recurrence, thus making rechallenge with temozolomide a 
viable option for patients with MGMT methylated glioblastoma and prolonged 
progression-free survival with first-line radiochemotherapy [49]. Changes of MGMT 
promoter methylation status at recurrence have not been observed in studies 
comparing matched tissue samples [50]. Interestingly, the prognostic value of MGMT 
methylation was similar among patients receiving radiotherapy versus chemotherapy 
in subgroup analyses of two phase III trials in patients with anaplastic gliomas [51, 52], 
albeit more global DNA methylation analyses suggest a predictive role of methylation 
of two specific CpG sites in the MGMT promoter for benefit from PCV [53]. However, 
the number of samples in this cohort was small and warrants confirmatory analyses. 
Overall, the role of MGMT promoter methylation status in WHO grade II and grade III 
gliomas remains a matter of controversy. 
 Histone H3.3 (H3F3A) K27 and G34 mutations. Point mutations in the 2 critical 
aminoacids K27 and G34 of the gene encoding histone H3.3 define IDH wild-type 
glioma subtypes in children and adolescents with G-CIMP negative gene methylation 
patterns that arise from distinct anatomical compartments [21, 54]. K27 and G34 
mutations are mutually exclusive and strongly associated with mutations of the tumor 
suppressor gene TP53 [21]. The strong anatomical and molecular association 
prompted the inclusion of H3F3AK27M mutant diffuse midline glioma as a novel entity to 
the 2016 WHO classification [3]. K27 mutations confer a poor prognosis, which may in 
part be attributed to the poorer surgical accessibility of midline tumors, but to date, no 
therapeutic implications derive from the presence of H3F3A mutations.  
 
Molecular subtypes derived from integrated large-scale analyses. The complexity 
of diffuse gliomas is not fully captured by marker-based sub-classification. Integrated 
gene expression and genomic analyses defined 4 glioblastoma subtypes that were 
associated with distinct genomic alterations and that were termed neural, proneural, 
classical and mesenchymal based on similarities to previously defined developmental 
gene expression signatures [55]. Unsupervised cluster analyses of subsequent 
independent datasets did not reproduce the segregation of the neural subtype 
signature as a distinct entity [21, 56], but further integration of methylation data defined 
a total of 6 subtypes, including 4 that clustered with proneural gene expression and 
are more common in children or young adults [21]. IDH mutated glioblastomas were 
the only proneural glioblastomas to confer a favorable prognosis, whereas the 
prognostic less favorable subtypes with proneural gene expression were characterized 
by H3F3A mutations in the codons of the critical amino acids K27 or G34, or by 
amplification of the gene encoding platelet derived growth factor receptor A 
(PDGFRA). PDGFRA amplified glioblastomas were designated receptor tyrosine 
kinase (RTK) I, as opposed to the non-proneural RTK II subtype that is characterized 
by a classical gene expression pattern and amplification of the receptor tyrosine kinase 
EGFR, and both RTK I and RTK II subtypes are furthermore associated with deletions 
of the cyclin-dependent kinase inhibitor 2A (CDKN2A) tumor suppressor gene and 
poor prognosis. The mesenchymal subtype shows a lower rate of copy-number 
alterations and no characteristic mutations, but likewise confers poor prognosis [21]. 
More recently, the applicability of these glioblastoma-based classifications to the entire 
histological spectrum of diffuse oligodendroglial and astrocytic diffuse gliomas was 
confirmed and two further prognostic subgroups were identified: (i) A small subgroup 
of IDH mutated astrocytic gliomas with poor prognosis that do not exhibit the 
characteristic G-CIMP gene methylation pattern, but are instead characterized by cell 
cycle activation due to CDKN2A deletions and cyclin dependent kinase 4 (CDK4) 
amplifications, and (ii) a small subgroup IDH wild-type WHO grade II/III astrocytic and 
oligodendroglial tumors in mostly young adults with favorable prognosis that share 
epigenetic and genomic features of pilocytic astrocytomas [6]. Such large-scale 
analyses rely on data derived from entire tissue samples, but another level of 
complexity is added by the extensive spatial and temporal molecular heterogeneity of 
gliomas [4, 5, 31].  
 
 
Avenues and challenges of molecular targeted therapies in diffuse gliomas 
 
The perspective of specifically targeting disease drivers in diffuse gliomas evoked 
high hopes for future effective treatments, but to date such attempts have failed 
beyond early phase studies. The paramount reason for this failure is the molecular 
complexity and heterogeneity of diffuse gliomas, but a broad range of factors that 
can be overcome by careful planning of clinical trials have had their share, too. For 
example, pharmacokinetic and pharmacodynamics issues have complicated early 
trials of EGFR inhibition in glioblastoma: The glioma-specific EGFRvIII deletion 
mutation that is present in half of all EGFR amplified glioblastomas yields 
constitutive, ligand-independent receptor activity that is not targeted by the EGFR 
inhibitors erlotinib or gefitinib, whereas brain penetration of the EGFRvIII inhibitor 
lapatinib is limited [57]. Another challenge in establishing molecular targeted 
therapies is posed by the choice of hypothesis-based or empirical molecular entry 
controls to chose patients that will potentially benefit from a trial drug. For example, 
the mammalian target of rapamycin (mTOR) inhibitor temsirolimus (CCI-779) failed to 
improve outcome in two separate phase II trial cohorts, whereas response was 
associated with phosphorylation of mTORSer2448 in newly diagnosed MGMT 
unmethylated glioblastoma [58] and with phosphorylation of the mTOR target S6-
kinase in recurrent glioblastoma [59], and efficacy studies further exploring mTOR 
inhibition in glioblastoma patients pre-selected for these molecular markers are 
currently probably not underway.  
Finally, chosing the right target poses the most difficult challenge to clinical trials that 
aim at specifically targeting the molecular machinery of cancers. In consideration of 
the extensive vascularity of glioblastomas, targeting signaling through the key 
molecular signaling molecule vascular endothelial growth factor (VEGF) was 
explored extensively, but a total of six phase III trials in newly diagnosed and 
recurrent glioblastoma failed to demonstrate an overall survival benefit from anti-
angiogenic therapy targeting either the VEGF or other putative angiogenic pathways 
[60-65]. Molecular analyses have however identified the proneural gene expression 
signature as a potential molecular marker for the benefit of an adjunct of the anti-
VEGF antibody bevacizumab to standard chemoradiotherapy in newly diagnosed 
glioblastoma [66], but a confirmatory trial that applies this signature prospectively is 
currently not planned and the opportunity to validate this finding in the RTOG 0825 
trial is pending. Considering the prominent role of epigenetic mechanisms in the 
pathophysiology of diffuse gliomas, measures to induce epigenetic reshaping were 
successfully applied in preclinical studies, including a small molecule inhibitor of 
mutant IDH [67] and an inhibitor of the K27 demethylase JMJD3, which yielded K27 
hypermethylation and potent anti-tumor activity in a pre-clinical model of H3 K27M–
mutant diffuse midline glioma [68], but clinical trials to test these inhibitors await to be 
completed. 
Immunotherapy approaches have recently moved into the focus of novel 
developments in oncology: In patients with metastatic melanoma and non-small-cell 
lung cancer, monoclonal antibodies directed against the immunosuppressive T-cell 
receptors programmed death protein (PD)1 (nivolumab, pembrolizumab) or cytotoxic 
T-lymphocyte antigen (CTLA) 4 (ipilimumab) have proven a successful strategy to 
improve survival by promoting innate immune-mediated anti-tumor activity [69-73]. 
The efficacy of nivolumab is currently being assessed in newly diagnosed 
glioblastoma as a substitute for temozolomide in patients with an unmethylated 
MGMT promoter in the phase III trial CheckMate 498 (NCT02617589), and as an 
adjunct to temozolomide in patients with a methylated MGMT promoter in the phase 
II trial CheckMate 548 (NCT02667587). Furthermore, the phase III trial CheckMate 
143 assessed the efficacy of nivolumab versus bevacizumab in patients with 
recurrent glioblastoma (NCT02017717). 
Vaccination against tumor antigens is another immunotherapy approach that is being 
explored in glioblastoma. The double-blinded phase II ICT-107 trial explored the 
safety and efficacy of a vaccine consisting of autologous dendritic cells that were 
pulsed with six tumor-associated peptides to trigger an anti-tumor T-cell response in 
newly diagnosed glioblastoma. The adjunct of this vaccine to standard 
chemoradiotherapy prolonged progression-free survival by 2.4 months without 
relevant safety issues [74] and therefore led to a similar phase III trial 
(NCT02546102). The DCVax trial is a phase III trial that assesses the efficacy of 
vaccination with dendritic cells that were pulsed with patients’ tumor lysates 
(NCT00045968). Using peptides for vaccination that occur specifically in tumor cells 
due to coding mutations potentially prevents cross reactivity of an elicited immune 
response against normal host cells and renders immune tolerance less likely. 
However, due to the multi-branched ontology of diffuse gliomas, only few mutations 
that were acquired early during gliomagenesis are present in all clones [5], such as 
mutant IDH which could be targeted successfully in a pre-clinical glioma model [75]. 
In contrast, clonal selection is a likely mechanism of resistance to vaccines that aim 
to elicit immune responses against mutations acquired later during gliomagenesis, 
such as the EGFRvIII deletion. This limitation may underly the lack of efficacy of 
vaccination with the EGFRvIII-specific peptide rindopepimut as an adjunct to 
standard chemoradiotherapy in newly diagnosed EGFRvIII-positive glioblastoma 
(NCT01480479), albeit the same vaccine appeared to prolong survival as an adjunct 
to the anti-angiogenic and probably pro-immunogenic anti-VEGF antibody 
bevacizumab in the phase II ReACT trial in patients with recurrent glioblastoma [76].  
The term adoptive T-cell transfer refers to an immunotherapy approach that exploits 
the in vitro expansion or genetic engineering of T-cells directed against tumor-
associated or tumor-specific peptides, and chimeric antigen-receptor (CAR) T-cells 
are genetically engineered cells that furthermore circumvent the need for co-
stimulatory molecules by linking antigen-binding domains directly to intracellular 
signaling domains that trigger T-cell activation [77]. A phase I trial in glioblastoma 
patients utilizing CAR T-cells directed against Her2 is ongoing (NCT01109095) and 
another trial utilizing CAR T-cells directed against EGFRvIII has suspended 
recruitment (NCT01454596).  
In summary, the current quest for effective and feasible treatment modalities and 
targets is yet at the onset of the personalization of treatments in patients with diffuse 
gliomas. Probably only combination treatments guided by molecular fingerprints that 
predict or capture clonal heterogeneity will be able to overcome resistance, but a 
plethora of issues including logistic feasibility and toxicity will have to be resolved along 
this development. 
 
 Figure 1. Overview of molecular subtypes of diffuse gliomas. The layered 
classification included in the 2016 WHO classification is depicted in red. 
Diffuse gliomas are segregated by IDH mutation status. 1p/19q codeletion 
marks oligodendrogliomas and the H3F3AK27 mutation marks diffuse midline 
gliomas. These molecular assessments trump histological tumor grades II-IV. 
Other less robust genetic and genomic (green), epigenetic (blue) and gene 
expression (yellow) patterns that have not been included in the WHO 
classification have been defined to further segregate diffuse gliomas based on 
molecular features. Relative prognosis and age associations are depicted at 
the bottom.
Table 1. Gliomas in the 2016 WHO classification of primary tumors of the central nervous system [3]. 
 
Entity Histological  
WHO 
grade 
Median overall 
survival  
First line therapy Comments 
     
Diffuse astrocytic and 
oligodendroglial tumours 
    
     
Diffuse astrocytoma,  
IDH mutant 
II > 10 years [78] 
 
Watchful waiting [40] or RTPCV 
[79] or (TMZ)/RTTMZ per 
extrapolation from WHO grade III 
gliomas [80] 
The previous term fibrillary 
astrocytoma is discouraged, because 
fibrillary morphology is the classical 
appearance and not a variant.  
Gemistocytic astrocytoma, 
IDH mutant  
II < 4 years [81] RTPCV [79] or (TMZ)/RTTMZ 
per extrapolation from WHO grade III 
gliomas [80]  
Variant of diffuse astrocytoma.  
Higher incidence of progression to 
IDH-mutant anaplastic astrocytoma 
and glioblastoma has been reported 
[81].  
Survival times including IDH-mutation 
status have not been reported. 
Watchful waiting strategies may not 
be adequate, if less favorable 
prognosis is confirmed in IDH 
mutated gemistocytic astrocytoma. 
Diffuse astrocytoma,  
IDH wild-type 
II > 5 years [79] RTPCV [79] or TMZ/RTTMZ per 
extrapolation from IDH wild-type 
glioblastoma [46] 
Rare, provisional entity comprising a 
variety of molecular subtypes mostly 
resembling IDH wild-type 
glioblastomas [20, 82]. 
Watchful waiting strategies are 
probably not adequate. 
Survival times have not been 
reported. 
Diffuse astrocytoma, NOS II 4-5 years [1] RTPCV [79] or (TMZ)/RTTMZ 
per extrapolation from WHO grade III 
gliomas [80] 
 
     
Anaplastic astrocytoma, 
IDH mutant 
III 5-10 years [33, 
78] 
(TMZ)/RTTMZ [80] No population-based survival data 
reported. 
Anaplastic astrocytoma, 
IDH wild-type 
III 2-4 years [26, 
33, 83] 
 
TMZ/RTTMZ per extrapolation from 
IDH wild-type glioblastoma [46], 
possibly RT alone in MGMT 
unmethylated patients [84] 
Molecularly resembling IDH wild-type 
glioblastoma, TERT promoter 
mutations confer poor prognosis [20, 
82]. 
No population-based survival data 
reported. 
Anaplastic astrocytoma, 
NOS 
III 1-2 years [1] (TMZ)/RTTMZ [80]  
     
Glioblastoma, IDH wild-type  IV 11-15 months 
[33, 85, 86] 
TMZ/RTTMZ [46, 47], > 65-70 
years RT (MGMT unmethylated), or 
TMZ (MGMT methylated), if 
combination therapy is not deemed 
feasible [27, 28] 
Histological variants: Giant cell 
glioblastoma, gliosarcoma, epitheloid 
glioblastoma 
 
 
Glioblastoma, IDH mutant IV 2-3 years [33, 
85] 
(TMZ)/RTTMZ per extrapolation 
from IDH mutant anaplastic 
astrocytoma [80] 
 
Glioblastoma, NOS IV < 1 year [1, 86] See above   
     
Diffuse midline glioma, H3-
K27M mutant 
IV < 1 year [21] TMZ/RTTMZ per extrapolation from 
IDH wild-type glioblastoma [46, 47] 
No population-based survival data 
reported. 
     
Oligodendroglioma, IDH 
mutant and 1p/19q 
codeleted 
II > 10 years [79] Watchful waiting [40] or RTPCV 
[79] 
No population-based survival data 
reported. 
Oligodendroglioma, NOS II > 10 years [1, 
87] 
Watchful waiting [40] or RTPCV 
[79] 
 
     
Anaplastic 
oligodendroglioma, IDH 
mutant and 1p/19q 
codeleted 
III > 10 years [38, 
39, 83] 
RTPCV [38, 39] No population-based survival data 
reported. 
Anaplastic 
oligodendroglioma, NOS 
III 5-7 years [1, 
83] 
RTPCV [38, 39]  
     
Oligoastrocytoma, NOS II < 7 years [81] Watchful waiting [40] or RTPCV 
[79] per extrapolation from 1p/19q 
codeleted oligodendroglioma 
Large interobserver variability of 
histological diagnosis [36, 88]. 
Anaplastic 
oligoastrocytoma, NOS 
III > 5 years [89]  RTPCV [38, 39] per extrapolation 
from 1p/19q codeleted anaplastic 
oligodendroglioma 
Large interobserver variability of 
histological diagnosis [36, 88] 
No population-based survival data 
reported. 
     
NOS, not otherwise specified (Histological diagnosis in cases where molecular data have not been fully assessed) 
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